Rogers Paul, Merenda Christine, Araojo Richardae, Lee Christine, Lolic Milena, Zhang Ying, Reese Jessica, Malloy Kimberly, Wang Dong, Zou Wen, Xu Joshua, Lee Elisa
National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, AR, USA.
Office of the Commissioner, Office of Minority Health and Health Equity, U.S. Food and Drug Administration, Silver Spring, MD, USA.
J Racial Ethn Health Disparities. 2024 Dec 27. doi: 10.1007/s40615-024-02261-0.
The Charlson Comorbidity Index (CCI) is a frequently used mortality predictor based on a scoring system for the number and type of patient comorbidities health researchers have used since the late 1980s. The initial purpose of the CCI was to classify comorbid conditions, which could alter the risk of patient mortality within a 1-year time frame. However, the CCI may not accurately reflect risk among American Indians because they are a small proportion of the US population and possibly lack representation in the original patient cohort. A motivating factor in calibrating a CCI for American Indians is that this population, as a whole, experiences a greater burden of comorbidities, including diabetes mellitus, obesity, cancer, cardiovascular disease, and other chronic health conditions, than the rest of the US population.
This study attempted to modify the CCI to be specific to the American Indian population utilizing the data from the still ongoing The Strong Heart Study (SHS) - a multi-center population-based longitudinal study of cardiovascular disease among American Indians. A 1-year survival analysis with mortality as the outcome was performed using the SHS morbidity and mortality surveillance data and assessing the impact of comorbidities in terms of hazard ratios with the training cohort. A Kaplan-Meier plot for a subset of the testing cohort was used to compare groups with selected mCCI-AI scores.
A total of 3038 Phase VI participants from the SHS comprised the study population for whom mortality and morbidity surveillance data were available through December 2019. The weights generated by the SHS participants for myocardial infarction, congestive heart failure, and high blood pressure were greater than Charlson's original weights. In addition, the weights for liver illness were equivalent to Charlson's severe form of the disease. Lung cancer had the greatest overall weight derived from a hazard ratio of 8.31.
The mCCI-AI was a statistically significant predictor of 1-year mortality, classifying patients into different risk strata χ (8, N = 1,245) = 30.56 (p = 0.0002). The mCCI-AI was able to discriminate between participants who died and those who survived 73% of the time.
查尔森合并症指数(CCI)是一种常用的死亡率预测指标,基于一个自20世纪80年代末以来健康研究人员使用的患者合并症数量和类型的评分系统。CCI的最初目的是对合并症进行分类,这些合并症可能会在1年时间范围内改变患者的死亡风险。然而,CCI可能无法准确反映美国印第安人的风险,因为他们在美国人口中占比小,且在最初的患者队列中可能缺乏代表性。为美国印第安人校准CCI的一个推动因素是,总体而言,该人群比美国其他人群承受着更大的合并症负担,包括糖尿病、肥胖症、癌症、心血管疾病和其他慢性健康状况。
本研究试图利用仍在进行的强心研究(SHS)的数据,对CCI进行修改,使其适用于美国印第安人群体。SHS是一项基于多中心人群的美国印第安人心血管疾病纵向研究。使用SHS发病率和死亡率监测数据进行以死亡率为结局的1年生存分析,并在训练队列中根据风险比评估合并症的影响。使用测试队列子集的Kaplan-Meier图比较具有选定mCCI-AI分数的组。
来自SHS的总共3038名第六阶段参与者构成了研究人群,截至2019年12月可获得他们的死亡率和发病率监测数据。SHS参与者为心肌梗死、充血性心力衰竭和高血压生成的权重高于查尔森的原始权重。此外,肝病的权重与查尔森对该疾病严重形式的权重相当。肺癌的总体权重最大,风险比为8.31。
mCCI-AI是1年死亡率的统计学显著预测指标,将患者分为不同风险分层χ(8,N = 1245)= 30.56(p = 0.0002)。mCCI-AI能够在73%的时间内区分死亡参与者和存活参与者。